Niacin Revived as Option for Treating Hyperlipidemia


Niacin Revived as Option for Treating Hyperlipidemia
May 21, 2013


Niacin may still be a viable therapy in preventive cardiology, despite the findings of no benefits and a signal of harm in the recently stopped Heart Protection Study2—Treatment of HDL to Reduce Incidence of Vascular Events (HPS2-THRIVE) trial, according to these commentators. They note that including the prostaglandin-inhibitor laropiprant in the trial may have negated some of niacin’s benefits. Niacin therapy may be on life support, they admit, but perhaps it should be be resuscitated.

RESULT: Niacin Therapy Lives for Another Day—Maybe?
Journal of the American College of Cardiology | May 28, 2013 (FREE FULL TEXT)

In addition to the effects of niacin in raising high-density lipoprotein (HDL) cholesterol and lowering low-density lipoprotein (LDL) cholesterol and triglycerides, this recent large, systematic review and meta-analysis reported reductions in major cardiovascular disease by 34% and coronary heart disease events by 25% with niacin therapy. The authors state that the consensus perspective derived from available clinical data supports an effect of niacin in reducing cardiovascular disease events.

Niacin Revived as Option for Treating Hyperlipidemia -

A mg twice a day keeps the CVE away. :)
Last edited: